High expression of PD-L1 at PD of NSCLC patients during osimertinib therapy indicates that immunotherapy could be effective in NSCLC patients positive for EGFR mutations that develop resistance to osimertinib [86]. Here, EGFR is linked to non-small cell lung carcinoma.